In conclusion, we present a novel regulatory role of RIG-I in the development of obesity and metabolic disorders, further suggesting that the modulation of RIG-I activity would provide an effective therapeutic strategy for the treatment of metabolic diseases. The gene discussed is RIGI; the disease is obesity due to melanocortin 4 receptor deficiency.